Egret Therapeutics

Egret Therapeutics is an early-stage biotech leveraging small molecule modulation of innate immunity to treat acute neurological injuries and disorders. Founded in 2021, the company is in a pre-clinical or very early clinical stage, targeting the significant unmet need in stroke recovery and related cognitive deficits. As a private, pre-revenue entity, its success hinges on validating its novel mechanism, advancing a lead candidate into clinical trials, and securing further investment. The company operates in the competitive but high-potential neuroimmunology space.

Small molecule platform targeting modulation of the innate immune system to treat neurological disorders arising from acute injury and inflammation.

The neuro-immunology and stroke therapeutic space is highly competitive, with numerous biopharma companies and academic centers pursuing various approaches, including antibodies, cell therapies, and other small molecules. Egret will need to demonstrate clear differentiation in efficacy or safety.